Objective: Speci®c immunological responses may be involved in the process of cryopreserved allograft valved conduit (AVC) degeneration, which is more frequently seen in young recipients. Rejection of heart and corneal allografts is preceded by an increase in the fraction of cytotoxic T lymphocytes (CTL) with high avidity for donor human leukocyte antigens (HLA) circulating in both peripheral blood and the affected graft. These donor-speci®c high-avidity CTLs are regarded as the destructive cells capable of causing graft damage. To monitor the precursors of these cells (CTLp) in young and adult AVC recipients, in vitro quantitative tests were performed on sequentially taken blood samples to quantitate CTLp frequencies and their avidity for donor antigens. Method: Six children and nine adults who received a cryopreserved AVC in the period between 1994 and 1997 were included in the study. From these patients, two to six blood samples were obtained up to 3 years after valve implantation. The number of circulating CTLp present within the peripheral blood mononuclear cell (PBMC) population was determined by limiting dilution analysis (LDA). The fraction of CTLp with high avidity for donor HLA class I was determined by addition of CD8 monoclonal antibodies (mAb) during the cytotoxic phase of the assay. Third-party stimulator cells were used to verify the donor-speci®city of the response. Results: The number of donor-speci®c CTLp increased signi®cantly in the period 6±12 months after AVC implantation, while third-party-speci®c CTLp frequencies were not affected. Additionally, we found a signi®cant increase of the high-avidity fraction of CTLp directed against donor antigens as early as during the ®rst 6 months after AVC implantation. The fraction of high-avidity CTLp remained signi®cantly higher post-compared with pre-implantation, even after 12 months. We observed no signi®cant difference in the kinetics of CTLp frequencies between pediatric and adult AVC recipients. Conclusion: Implantation of cryopreserved human AVC induces an increase in the total number of circulating CTLp directed against donor HLA class I in both adults and children. The shift towards more destructive high-avidity CTLp in the peripheral blood indicates their potential damaging effect towards the heart valve allograft. q
Introduction
Allograft valved conduits (AVC) or heart valve allografts have been used in the last three decades as biological valve prosthesis in the surgical treatment of acquired or congenital heart valve diseases. Several follow-up studies of AVC recipients have revealed good clinical results in the adult population, although in the long run the majority of the grafts showed primary tissue failure [1] . In the pediatric population however, the observed early onset of graft failure resulting in allograft replacement is a serious problem [2] . A speci®c immunological response of the recipient against the AVC has been suggested as one of the main causes for allograft degeneration, because AVC implantation is performed without HLA or blood group matching and in the absence of immunosuppressive therapy. Morphological studies of early and late AVC explants have demonstrated the involvement of immune competent cells like T and B lymphocytes as well as macrophages in the valve lea¯ets and arterial wall of AVC [3, 4] . Induction of donor-speci®c antibodies against HLA class I and II antigens after AVC implantation also con®rms activation of cellular and humoral immune responses [5] . A causal relationship between an active immune response of the recipient and rejection of the allograft is dif®cult to prove, since histological con®rmation of rejections are not possible.
In heart transplantation, the fraction of precursor cytotoxic T lymphocytes (CTLp) with high avidity for donor antigens within the total CTLp population, was found to be increased in peripheral blood of the recipients and in myocardial tissue during rejection [6] . A similar increase in the fraction of donor-speci®c high-avidity CTL was found in patients rejecting their corneal grafts [7] . Therefore, these CTLp with high avidity for donor antigens are regarded as the major effector cells capable of causing graft damage. Since there is a difference in clinical outcome between pediatric and adult AVC recipients it has been suggested that children are able to mount a more vigorous immune response [2, 3] .
In an attempt to explain the possible differences in immune response between children and adults, which could lead to destruction of a human AVC, we studied the kinetics of the frequency of CTLp and their avidity in peripheral blood of pediatric and adult AVC recipients.
Materials and methods

Cardiac allograft valved conduit
Aortic and pulmonary allograft valved conduits (AVC) consisting of the complete arterial root including semilunar valves, arterial wall and a minor muscular rim were obtained from multi-organ donors and non-heart beating donors within 24 h after circulatory arrest and from so called domino hearts from heart transplant recipients. Sterile preparation of the AVC was in conformity with the standard operating procedures of the Heart Valve Bank Rotterdam, The Netherlands. After dissection, the AVC were sterilized for 6 h at 378C in Medium 199 (Bio-Whittaker, Verviers, Belgium) containing: 12 mg/ml vancomycin (Eli Lilly), 30 mg/ml¯ucytosin (Hoechst Pharma), 12 mg/ml amikacin (Bristol-Myers-Squibb), 12 mg/ml metronidazol (RhonePoulenc-Rorer) and 3 mg/ml cipro¯oxacin (Bayer). Subsequently, the allografts were cryopreserved according to the standard cryopreservation protocol of the Heart Valve Bank Rotterdam (218C/min) in Medium 199 with 10% dimethylsulfoxide (DMSO, Sigma, St. Louis, MO) and stored in the vapor phase of liquid nitrogen (2150 to 21808C). Before implantation, the allografts are rapidly thawed in a 378C Medium 199 bath followed by stepwise dilution of the DMSO from the tissue in cold Medium 199.
Patients
Six children (aged under 16 years) and nine adults (older than 16 years), who received a cryopreserved cardiac AVC between June 1994 and September 1997, were included in the study after informed consent. The average age of the patients in the adult group was 40.2 years (range 25±57), and 9.3 years (range 3±16) in the children group. In the adult group, four patients received a cryopreserved aortic AVC and ®ve patients an allograft of pulmonary origin. In all pediatric recipients, cryopreserved pulmonary AVC were used for reconstruction of the right ventricular out¯ow tract. Tables 1 and 2 summarize the characteristics of the patients and the indication for AVC implantation. During this study none of the patients were treated with long-term immunosuppressive therapy. The Medical Ethical Committee of the University Hospital Rotterdam and the Medical Faculty of the Erasmus University Rotterdam approved this study.
Peripheral blood mononuclear cells (PBMC) and spleen cell sampling
From each patient, two to six heparin-treated blood samples were obtained at different time points up to 3 years after AVC implantation. The ®rst blood sample was Spleen cells were obtained by mechanical dissociation of small pieces of spleen from the AVC donor through a sieve in RPMI 1640 medium (Bio-Whittaker) containing 10 mg/ml DNAse (Boehringer Mannheim, Mannheim, Germany) to prevent aggregation of cells. Subsequently, the cell suspension was ®ltrated through a 40-mm cell strainer (Falcon, Franklin Lakes, NJ) and washed. Thereafter, the spleen cells were centrifuged over a Ficoll-Paque (Amersham) density gradient, collected, washed and stored at 21408C.
Limiting dilution analysis
Limiting dilution cultures were set up in 96-well Ubottom culture plates (Nunclon, Roskilde, Denmark) [8] . Twenty-four replicates of graded number of responder cells (recipient PBMC) were titrated in 7 steps of 1:1 dilutions starting from 4 £ 10 4 to 625 PBMC per well. To study the speci®city of the cytotoxic response two sets of dilution series were performed. In one series 4 £ 10 4 irradiated (45 Gy) donor or donor HLA-matched (donor-like) spleen cells were added as stimulator cells. In the other series 4 £ 10 4 irradiated (45 Gy) donor HLA-mismatched (third-party) spleen cells per well were used as stimulator cells. All wells contained a total volume of 200 ml culture medium, consisting of RPMI 1640 Dutch Modi®cation (Bio-Whittaker), supplemented with 2 mM l-glutamine (Gibco BRL, Scotland, UK), 100 IU/ml penicillin (Bio-Whittaker), 100 mg/ml streptomycin (Bio-Whittaker) and 10% pooled human serum. After 3 days of culturing, 100 ml of the culture medium was refreshed with culture medium supplemented with 40 units/ml recombinant human interleukin-2 (Proleukin; Chiron BV, Amsterdam, The Netherlands).
Cell-mediated lympholysis
After 10 days, the microcultures were split in two equal parts (80 ml). One half of the split wells was tested for cytotoxicity in the absence of CD8 monoclonal antibodies (mAb) and the other half was tested in the presence of CD8 mAb. Each well was individually tested for cytolytic activity against 5 £ 10 3 Europium (Eu-DTPA; Fluka, Buchs, Switzerland and Sigma, St. Louis, MO) labeled target cells [9] . After donor stimulation, T-cell blasts of donor origin were used as targets, whereas third-party stimulated responder PBMC received T-cell blasts of third-party origin. After 4 h of incubation at 378C in a humidi®ed atmosphere with 5% CO 2 , 20 ml of supernatant was harvested and transferred into 96-well¯at-bottom microtiter plates with low background¯uorescence (Fluoroimmunoplate, Nunclon). Subsequently, 100 ml Enhancement solution (Wallac, Turku, Finland) was added to each well and thē uorescence of the released Europium was measured in a time-resolved¯uorometer (Victor 1420 Multilabel Counter, Wallac, Finland). Fluorescence was expressed in counts/s. As a control for each target cell, spontaneous lysis (target cells 1 culture medium) and maximum lysis (target cells 1 1% Triton X-100) was determined. The fraction of CTLp with high avidity for donor or third-party HLA class I antigens was calculated using the formula: % CTLp with high avidity 100% £ CTLp frequency with CD8 CTLp frequency without CD8
Target cells
T-cell blasts were obtained by culturing donor or thirdparty spleen cells for 7 days in culture medium supplemented with 1% phytohemagglutinin (PHA; Difco Laboratories, Detroit, MI,) and 10% v/v lymphocult-T (Biotest AG, Dreieich, Germany). Then, the T-cell blasts were labeled with Europium as reported previously by Bouma et al [9] These T-cell blasts can be used to determine donor HLA class I (but not class II) directed cytotoxicity [6] . 3 subclass, which recognizes the gp32 chain of the CD8 molecule [10] . In this study, a concentration of approximately 1 mg IgG 3 /well of FK18 mAb obtained from culture supernatant of the Tecnomouse system (Tecnomara-Integra Bioscience, Wallisellen, Switzerland) was used. This concentration inhibited the cytotoxic capacity of CD8-dependent CTLp clones but had no effect on cell lysis by CD8-independent CTLp clones [6] .
Statistical analysis
Experimental wells were scored positive, if the counts of the well exceeded the mean counts=s 1 3 £ SD of the 24 wells in which only stimulator cells were present. For each responder cell concentration the number of negative wells were determined and used to calculate the frequency with a statistical program designed by Strijbosch et al. [11] . The CTLp frequency (expressed as the number of CTLp per 10 6 PBMC) and the 95% con®dence interval (CI) were calculated by the Jackknife procedure for maximal likelihood. The post-operative follow up is divided into three periods: 1±6 months, 6±12 months and . 12 months. When a time period included multiple blood samples of one patient the average of the analyzed frequencies was calculated. The signi®cance of differences in CTLp frequencies or the percentage of high-avidity CTLp against donor or third-party antigens at different periods after AVC implantation was analyzed by the Mann±Whitney U-test. The paired Wilcoxon signed rank test was used to evaluate the frequency kinetics in both children and adult group. Twosided P-values of 0.05 or less were considered signi®cant.
Results
Follow-up of valve allograft recipients
From one adult (V.N.) and one pediatric (V.M.) AVC recipient the follow-up period was less than 6 months, because they stopped visiting the outpatient department at 3.5 months ( Table 3 ). The mean follow-up period of the adult patients was 19.8 months (range 3.5±36.5 months) and 19.0 months (range 4.7±35.5 months) for the pediatric group. From two pediatric patients (H.Z., B.X.) we did not receive blood samples in the period 1±6 months and 6±12 months, respectively. From one adult patient (H.R.) the 1±6 months blood sample was not available. At the time of completion of this study all patients are still alive.
CTLp frequency in peripheral blood
The number of donor-speci®c CTLp per million PBMC, the CTLp frequency, of all 15 patients increased in time compared with the pre-operative value. This was not related to the amount of blood transfusions each patient received (Table 1 ). In the period 6±12 months after AVC implantation the CTLp frequencies were maximal and signi®cantly higher than before implantation (P 0:01; Table 3 ). In 12 patients the pre-implantation CTLp frequencies were below 50, and for three AVC recipients (H.R., S.T. and V.M.), they exceeded 100 CTLp per million PBMC. No signi®cant increase of CTLp frequencies against third-party antigens was observed at 1±6 (P 0:82), 6±12 (P 0:41) and . 12 (P 0:89) months after implantation (Fig. 1b) , indicating the donor speci®city of the CTLp response.
Fraction of CD8-independent (high-avidity) CTLp
Similar to the total frequency of donor-speci®c CTLp, the fraction of CTLp with high avidity for donor antigens varied between the 15 patients (Fig. 2) . In 13 out of 15 AVC recipients (86%) the percentage of donor-speci®c high-avidity CTLp post-operatively was higher compared with preimplantation values. It should be noted that from the two patients (V.N., V.M.) in whom the fraction high-avidity CTLp remained unchanged, the follow-up period was incomplete ( Table 3 ). The highest levels were observed at 6±12 months (P , 0:0001, Table 3 ). After the ®rst 12 months the fraction high-avidity CTLp declined in ®ve patients (Table 3) . Nevertheless, the median value remained signi®cantly higher compared with the pre-operative fraction (P 0:01; Table 3 ). 
Comparison of the frequency kinetics between pediatric and adult patients
The paired Wilcoxon signed rank test was used to determine the frequency kinetics of each patient group. In both pediatric and adult AVC recipients the CTLp frequencies increased in time (Fig. 1a) . Statistical analysis of the preand highest post-implantation values revealed P-values of 0.03 and 0.004 for children and adults, respectively. The kinetics in pediatric AVC recipients was comparable to that in adults, because the absolute increase of the CTLp frequency after AVC implantation (i.e. DCTLp frequency) in children and adults was not signi®cantly different during the three time periods, i.e. ®rst and second 6 months and after the ®rst year (Mann±Whitney U-test; P 0:44, P 0:21, P 0:07, respectively).
In the adult group the median fraction donor-speci®c high-avidity CTLp increased signi®cantly (P 0:008), whereas in the children group the increase was almost signi®cant (P 0:06) due to the small numbers of patients.
Comparison of the delta (D) increases of the fraction high-avidity CTLp in children versus adults, using the Mann±Whitney U-test, showed no signi®cant differences in the increase during the three observation periods (P 0:13, P 0:08, P 0:80).
Discussion
Since the introduction of cardiac AVCs as biological substitutes in valve replacement surgery, the risk of tissue degeneration due to immunological reactions has been a matter of debate. Viability preservation of AVCs has been suggested to improve durability [12] , while others promote preservation of the non-vital collagenous network as an important criteria for prolonged allograft durability [13] . Cryopreservation represents a cell-and tissue-protective preservation method, which preserves the cellular viability as well as the stromal structure. The question regarding the loss of the endothelium expressing HLA class I and II molecules remains unclear, since con¯icting results have been published [14, 15] In this clinical study, we could not assess the presence of viable endothelial cells in the pre-implantation AVCs. However, fresh as well as cryopreserved human aortic valve fragments or valve-derived endothelial cells were able to stimulate allogenic T cells in vitro [16] . Apart from vascular endothelial cells, dendritic cells have been identi®ed in cryopreserved human AVCs, which are capable of presenting foreign HLA class I and II antigens to recipient T cells [17] . Additionally, ®broblasts, smooth muscle cells and dendritic cells bearing HLA class I molecules have been found to be embedded in the matrix of heart valve lea¯ets [12, 18] . These cells can serve as antigen source to initiate an immune response by the indirect pathway [19] . The results of the present study demonstrate an overall increase of the total CTLp frequency in peripheral blood of all 15 patients during the ®rst year after cryopreserved AVC implantation (Fig. 1a) . These data again support the assumption that cryopreserved AVCs contain viable cells expressing HLA class I and II molecules, able to induce a donor-speci®c cellular and humoral immune response in the recipient [5] .
In heart transplant recipients, not the absolute increase in the number of circulating donor-speci®c CTLp but the increase of CD8-independent (high-avidity) CTLp within the CTLp population is associated with graft rejection [6] . It has been suggested that the strict immune-suppressive regimen of heart transplant recipients inhibits CTLp numbers, while destructive high-avidity CTLp that can break through the immune-suppressive barrier cause graft rejection. A similar increase of the donor-speci®c high-avidity CTLp fraction was seen in patients rejecting their corneal transplant graft, while in non-rejecting patients, only CD8-dependent (low avidity) CTLp were found in the peripheral blood [7] . The increase of the donor-speci®c high-avidity CTLp fraction in 13 out of 15 valve recipients in this study is consistent with these data and may imply a process of cell-mediated injury of the AVC.
By using an in vivo rat model, Green et al. have demonstrated in®ltration of AVCs by immune competent cells like T and B lymphocytes and macrophages, that are associated with rejection [20] . However, contradictory reports have been published over the years concerning descriptive morphological studies of clinical valve allograft explants. Mitchell and associates described only sparse mononuclear in¯ammatory cell in®ltration in 20 explanted cryopreserved valve allografts, which all appeared non-viable without endothelial or connective tissue cells. They suggested that immune responsiveness has no impact on allograft degeneration [13] . On the other hand, Rajani and colleagues demonstrated lymphocytic in®ltration in valve lea¯ets of ®ve valve allografts explanted due to structural failure within less than 8 months after implantation [4] . Others reported identical in®ltration of in¯ammatory cells in cryopreserved pulmonary valve allograft explants, while the aortic valve explants were free from any cellular component [3] . Finally, Hoekstra et al demonstrated donor-speci®c cytotoxicity of in®ltrating lymphocytes found in explanted AVC [21] . Also, reviewing these studies, severe structural failure associated with in®ltration of immune competent cells is more frequently seen in pediatric patients, in whom pulmonary AVC s are predominantly implanted right-sided. The question remains whether the higher incidence of structural failure is due to increased immune reactivity of the pediatric recipient, to intrinsic differences between cryopreserved pulmonary and aortic AVCs or to surgical techniques applied. The hypothesis of a more potent immune response in young children is not yet established and is not supported by this study. However, a recent study regarding pediatric renal transplantation demonstrated more rejection episodes and a greater irreversibility of rejection in younger recipients, supporting the hypothesis of an increased immune responsiveness [22] . Ettenger proposed higher functional indices of immune competent cells in children less than 5 years old as a cause for higher immune reactivity [23] . In our study, we have demonstrated a comparable increase in both the number of circulating CTLp and its high-avidity fraction within pediatric and adult patients. The small number of pediatric patients and the lack of patients, who reached de®ned end of analysis (i.e. re-operation or death due to severe valve degeneration) are both de®nite limitations of this single-center study. Apart from expanding the study population, further studies concerning the clinical consequences of such immunological activity have to be performed using relevant clinical parameters for structural valve failure [24] .
In conclusion, cryopreserved cardiac AVCs are able to promote an increase in the number of circulating CTLp speci®c for donor HLA class I antigens. The preferential expansion of the high-avidity fraction of CTLp that we have found, may re¯ect an ongoing process of cell-mediated destruction of the valve allograft tissue in situ, which ultimately may lead to or contribute to primary structural failure. We observed no differences in the kinetics of CTLp frequency between pediatric and adult recipients.
